Data / Drug companies / Samsung Biologics Co., Ltd.
Samsung Biologics Co., Ltd.: 60 products in the FDA NDC directory, labeler code 71124
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Samsung Biologics Co., Ltd. (labeler code 71124) lists 60 products in the FDA National Drug Code Directory. By type: 40 bulk ingredients, 20 drugs for further processing. Its main marketing category is bulk ingredients. The newest product started marketing on October 30, 2026.
The request: Watch Samsung Biologics Co., Ltd. (FDA labeler code 71124): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 71124
- Products in commercial distribution
- 60
- Packages
- 66
- Finished drugs by generic name
- 0
- Prescription products
- 0
- Over the counter products
- 0
- Started marketing in the last 12 months
- 9
- Earliest marketing start
- June 15, 2015
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Bulk ingredients | 40 | 66.7% |
| Drugs for further processing | 20 | 33.3% |
Products by type
| Type | Products | Share |
|---|---|---|
| Bulk ingredients | 40 | 66.7% |
| Drugs for further processing | 20 | 33.3% |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Liquid | 40 | 66.7% |
| Solution | 9 | 15% |
| Injection, solution | 4 | 6.7% |
| Injection, powder, lyophilized, for solution | 3 | 5% |
| Injection | 3 | 5% |
| Injection, suspension | 1 | 1.7% |
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Alirocumab | 71124-0066 | Liquid | Bulk ingredients | October 30, 2026 |
| Rilonacept | 71124-0037 | Liquid | Bulk ingredients | June 18, 2026 |
| Infliximab | 71124-0060 | Liquid | Bulk ingredients | March 20, 2026 |
| Sotatercept | 71124-0061 | Liquid | Bulk ingredients | March 4, 2026 |
| Rituximab | 71124-0053 | Liquid | Bulk ingredients | February 11, 2026 |
| Secukinumab | 71124-0065 | Liquid | Bulk ingredients | December 23, 2025 |
| Amivantamab | 71124-0056 | Liquid | Bulk ingredients | December 17, 2025 |
| Cosibelimab | 71124-0048 | Injection | Drugs for further processing | December 8, 2025 |
| Cosibelimab | 71124-0047 | Liquid | Bulk ingredients | December 8, 2025 |
| Trastuzumab | 71124-0046 | Liquid | Bulk ingredients | October 30, 2025 |
| Denosumab | 71124-0038 | Liquid | Bulk ingredients | October 10, 2025 |
| Nirsevimab | 71124-0033 | Liquid | Bulk ingredients | August 1, 2025 |
| Denosumab | 71124-0035 | Injection, solution | Drugs for further processing | July 1, 2025 |
| Donanemab | 71124-0045 | Liquid | Bulk ingredients | February 28, 2025 |
| Belimumab | 71124-0062 | Liquid | Bulk ingredients | January 1, 2025 |
| Bimekizumab | 71124-0055 | Liquid | Bulk ingredients | December 15, 2024 |
| Bevacizumab | 71124-0039 | Injection | Drugs for further processing | September 24, 2024 |
| Eculizumab | 71124-0034 | Injection, solution | Drugs for further processing | July 19, 2024 |
| Aflibercept-yszy | 71124-0032 | Liquid | Bulk ingredients | June 17, 2024 |
| Mirvetuximab | 71124-0052 | Liquid | Bulk ingredients | May 31, 2024 |
| Emicizumab | 71124-0057 | Injection, solution | Drugs for further processing | January 31, 2024 |
| Trastuzumab | 71124-0042 | Liquid | Bulk ingredients | December 28, 2023 |
| Rozanolixizumab | 71124-0049 | Liquid | Bulk ingredients | July 11, 2023 |
| Infliximab | 71124-0031 | Injection, powder, lyophilized, for solution | Drugs for further processing | July 8, 2023 |
| Adalimumab | 71124-0059 | Injection | Drugs for further processing | July 1, 2023 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.